# DNAJB5

## Overview
DNAJB5 is a gene that encodes the protein DnaJ heat shock protein family (Hsp40) member B5, which is part of the Hsp40 family of co-chaperones. This protein plays a crucial role in cellular stress responses and protein homeostasis by assisting Hsp70 proteins in the folding of nascent polypeptides and the refolding of misfolded proteins. DNAJB5 is primarily active in the cytoplasm and is involved in various cellular processes, including protein quality control and stress tolerance. It has been implicated in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), where it modulates protein aggregation, and in cancer, where it is associated with epithelial-mesenchymal transition in breast cancer cells (Uretmen2019Systemslevel; Dilliott2022DnaJC7; Rozales2021Differential). The gene's involvement in these pathways highlights its potential as a therapeutic target in managing protein misfolding and aggregation-related diseases.

## Function
DNAJB5, a member of the Hsp40 family, functions as a co-chaperone in protein folding and stress response. It assists Hsp70 proteins by stimulating their ATPase activity, which is crucial for the proper folding of nascent polypeptides and the refolding of misfolded proteins. This activity is essential for maintaining protein homeostasis and stress tolerance within cells. DNAJB5 is primarily active in the cytoplasm, where it plays a significant role in cellular processes related to protein quality control (Dilliott2022DnaJC7).

In the context of neurodegenerative diseases, DNAJB5 has been implicated in modulating protein aggregation. It has been observed to slightly aggravate the aggregation of ALS-related mutant FUS proteins, indicating its involvement in the complex network of chaperones that manage protein aggregation in neurodegenerative conditions (Rozales2021Differential). Additionally, DNAJB5 is part of a mesenchymal-specific network in breast cancer, showing higher expression in mesenchymal breast cancer cell lines and correlating with epithelial-mesenchymal transition (EMT) scores, although its specific function in healthy human cells remains less defined (Uretmen2019Systemslevel).

## Clinical Significance
DNAJB5, a member of the Hsp40 family, has been implicated in various diseases due to its role in protein homeostasis and cellular stress responses. Alterations in DNAJB5 expression have been associated with neurodegenerative diseases, such as Huntington's disease (HD). In HD models, DNAJB5, the human ortholog of the Drosophila protein CG5001, has been shown to reduce protein aggregation and improve the solubility of protein fractions, suggesting its potential as a therapeutic target for managing protein misfolding and aggregation, which are key features of neurodegenerative diseases (Deo2024Two). 

DNAJB5 is also noted as a novel biomarker and potential target for cervical cancer treatment. Knockdown studies in uterine tissue cells with squamous cell carcinoma have demonstrated that reduced expression of DNAJB5 leads to decreased cell proliferation and increased apoptosis, indicating its role in cancer cell survival and proliferation (Deo2024Two). 

These findings highlight the clinical significance of DNAJB5 in both neurodegenerative diseases and cancer, underscoring the importance of understanding its regulatory mechanisms and interactions to develop potential therapeutic strategies (Deo2024Two).

## Interactions
DNAJB5, a member of the Hsp40 family, is involved in interactions that modulate protein homeostasis and stress responses. It functions as a co-chaperone, primarily assisting Hsp70 proteins in protein folding and stress response processes. DNAJB5 has been shown to bind stably to soluble cytoplasmic TDP-43, a protein associated with neurodegenerative diseases like ALS, reducing both soluble and insoluble cytoplasmic TDP-43 levels. This interaction decreases the formation of TDP-43-positive puncta in cells, suggesting a role in mitigating TDP-43 aggregation (San2024A).

In experiments involving HEK293T cells, over-expression of DNAJB5 led to a significant decrease in both soluble and insoluble levels of TDP-43 variants, indicating that DNAJB5 affects TDP-43 at the protein level. This suggests a broad protective effect against TDP-43 pathology, as DNAJB5 over-expression also reduced levels of insoluble phosphoTDP-43 (San2024A).

While DNAJB5's interactions with other proteins or nucleic acids are not extensively detailed, its role in protein aggregation and interaction with TDP-43 highlights its potential importance in neurodegenerative disease pathways. The specific mechanisms of these interactions remain an area for further research.


## References


[1. (Dilliott2022DnaJC7) Allison A. Dilliott, Catherine M. Andary, Meaghan Stoltz, Andrey A. Petropavlovskiy, Sali M. K. Farhan, and Martin L. Duennwald. Dnajc7 in amyotrophic lateral sclerosis. International Journal of Molecular Sciences, 23(8):4076, April 2022. URL: http://dx.doi.org/10.3390/ijms23084076, doi:10.3390/ijms23084076. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23084076)

[2. (Uretmen2019Systemslevel) Zeynep Cansu Uretmen Kagiali, Erdem Sanal, Özge Karayel, Ayse Nur Polat, Özge Saatci, Pelin Gülizar Ersan, Kathrin Trappe, Bernhard Y. Renard, Tamer T. Önder, Nurcan Tuncbag, Özgür Şahin, and Nurhan Ozlu. Systems-level analysis reveals multiple modulators of epithelial-mesenchymal transition and identifies dnajb4 and cd81 as novel metastasis inducers in breast cancer. Molecular &amp; Cellular Proteomics, 18(9):1756–1771, September 2019. URL: http://dx.doi.org/10.1074/mcp.ra119.001446, doi:10.1074/mcp.ra119.001446. This article has 31 citations.](https://doi.org/10.1074/mcp.ra119.001446)

3. (Rozales2021Differential) Differential roles for DNAJ isoforms in HTT-polyQ and mutant FUS aggregation modulation revealed by chaperone network screens. This article has 0 citations.

[4. (San2024A) Rebecca San Gil, Dana Pascovici, Juliana Venturato, Heledd Brown-Wright, Prachi Mehta, Lidia Madrid San Martin, Jemma Wu, Wei Luan, Yi Kit Chui, Adekunle T. Bademosi, Shilpa Swaminathan, Serey Naidoo, Britt A. Berning, Amanda L. Wright, Sean S. Keating, Maurice A. Curtis, Richard L. M. Faull, John D. Lee, Shyuan T. Ngo, Albert Lee, Marco Morsch, Roger S. Chung, Emma Scotter, Leszek Lisowski, Mehdi Mirzaei, and Adam K. Walker. A transient protein folding response targets aggregation in the early phase of tdp-43-mediated neurodegeneration. Nature Communications, February 2024. URL: http://dx.doi.org/10.1038/s41467-024-45646-9, doi:10.1038/s41467-024-45646-9. This article has 1 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-024-45646-9)

[5. (Deo2024Two) Ankita Deo, Rishita Ghosh, Snehal Ahire, Sayali Marathe, Amitabha Majumdar, and Tania Bose. Two novel dnaj chaperone proteins cg5001 and p58ipk regulate the pathogenicity of huntington’s disease related aggregates. Scientific Reports, September 2024. URL: http://dx.doi.org/10.1038/s41598-024-71065-3, doi:10.1038/s41598-024-71065-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-71065-3)